Free Trial

Hoth Therapeutics Q2 2024 Earnings Report

Hoth Therapeutics logo
$0.82 +0.04 (+5.75%)
As of 03:59 PM Eastern

Hoth Therapeutics EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.39
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Hoth Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Hoth Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Hoth Therapeutics Earnings Headlines

Why Hoth Therapeutics Is Rising In Pre-market?
$24 trillion tech spotted at Mar-a-Lago?
President Trump’s Secret Service was recently spotted using an odd new technology at his home in Mar-a-Lago…
See More Hoth Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hoth Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hoth Therapeutics and other key companies, straight to your email.

About Hoth Therapeutics

Hoth Therapeutics (NASDAQ:HOTH), a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

View Hoth Therapeutics Profile

More Earnings Resources from MarketBeat